The North America Molecular Infectious Disease Testing Market was valued at USD 5,320 Million in 2025 and is projected to reach USD 10,900 Million by 2035, growing at a CAGR of 6.80% from 2024 to 2035. Driven by technological advancements, rising incidence of infectious diseases, and growing demand for rapid diagnostic solutions, the market is experiencing robust growth across the region.
The economic impact of tariffs on "North America Molecular Infectious Disease Testing Market".
Market Growth Drivers
Rising Incidence of Infectious Diseases: The increasing prevalence of infectious diseases such as influenza, HIV, hepatitis, and the resurgence of emerging pathogens have significantly driven demand for molecular infectious disease testing in North America. According to Roche Diagnostics, the recent surge in respiratory and vector-borne disorders has accelerated the adoption of their molecular-based diagnostic products, enabling faster and more accurate detection of pathogens. The heightened public health focus post-COVID-19 has further incentivized healthcare providers to adopt molecular diagnostics for effective disease management and outbreak control.
Technological Advancements in Molecular Diagnostics: Innovations in molecular testing platforms, such as the introduction of fully automated PCR systems and enhancements in sample-to-answer workflows, have transformed the landscape of infectious disease diagnostics. For example, Abbott Laboratories’ recent launch of the ID NOW™ COVID-19 rapid molecular test has significantly reduced turnaround time for results, supporting timely clinical decision-making. These technological upgrades have expanded the application of molecular testing from centralized laboratories to point-of-care settings, enhancing accessibility and scalability across the healthcare system.
Key Market Trends
Expansion of Point-of-Care Molecular Testing: The shift from centralized laboratory testing towards decentralized, point-of-care molecular diagnostics is redefining the infectious disease testing landscape. Companies such as Cepheid (a Danaher Corporation subsidiary) are leading this transformation with devices like the GeneXpert® system, which facilitates rapid, near-patient testing for diseases including COVID-19, tuberculosis, and MRSA. This trend is driven by the need for immediate, actionable results in various healthcare settings, improving patient outcomes and streamlining infection control protocols.
Integration of Artificial Intelligence in Test Interpretation: The adoption of artificial intelligence (AI) and machine learning tools for interpreting complex molecular diagnostic data is becoming increasingly prominent. BioFire Diagnostics, a subsidiary of bioMérieux, has integrated AI-driven algorithms into their multiplex PCR platforms, enabling faster data analysis and more precise detection of co-infections and drug resistance markers. This trend not only enhances diagnostic accuracy but also supports personalized treatment strategies and surveillance of infectious disease outbreaks.
Market Opportunities
Growth in Home-based Molecular Testing Solutions: The emerging demand for home-based molecular testing kits presents a significant opportunity. Companies like Lucira Health are introducing FDA-authorized self-administered molecular test kits for COVID-19 and influenza, addressing the need for convenient and remote diagnostics while reducing the burden on healthcare facilities.
Expansion into Emerging Pathogen Testing: The increasing focus on preparedness for future pandemics and emerging pathogens is opening new avenues for test developers. Thermo Fisher Scientific is investing in the expansion of their molecular infectious disease panels to include novel and rare pathogens, tapping into government and private sector collaborations focused on pandemic readiness.
North America Molecular Infectious Disease Testing Market Revenue (USD Million), 2020-2035
The revenue chart from 2020 to 2035 illustrates a steady upward trajectory in the North America Molecular Infectious Disease Testing Market. Beginning with USD 2,900 Million in 2020, the market shows consistent growth as investments in rapid diagnostic technologies, public health initiatives, and increased infectious disease awareness drive adoption. By 2025, revenue reaches USD 5,320 Million, reflecting accelerated demand driven by COVID-19, with the trend continuing upwards to USD 10,900 Million in 2035. The chart highlights periodic spikes that coincide with public health emergencies, technological launches, and broader implementation of point-of-care diagnostics across the region.
North America Molecular Infectious Disease Testing Market Share by Region, 2025
The 2025 market share pie chart reveals that the United States holds the dominant portion at 77% of the North America molecular infectious disease testing market. Canada follows with a 17% share, benefiting from expanding government healthcare initiatives and diagnostic capacity upgrades. Mexico occupies 4%, while other North American territories, including the Caribbean, comprise 2%. The distribution reflects the concentration of advanced molecular diagnostic infrastructure, major market players, and clinical research efforts in the US, whereas Canada and Mexico are experiencing promising growth through public-private collaborations and increased access to advanced diagnostics.
Recent Developments (Past 6 Months)
In May 2024, Cepheid, a division of Danaher Corporation, launched its Xpert® Xpress CoV-2/Flu/RSV Plus test in North America, expanding its multiplex molecular testing portfolio. The new test received Emergency Use Authorization from the US FDA and combines the detection of SARS-CoV-2, influenza A/B, and RSV into a single rapid molecular assay, enabling clinicians to differentiate between multiple respiratory infections at the point of care in under 45 minutes.
In March 2024, Abbott Laboratories received Health Canada approval for its Alinity m Resp-4-Plex molecular diagnostic test, which simultaneously detects and differentiates between COVID-19, influenza A, influenza B, and RSV. The Alinity m platform supports high-throughput, automated testing in large hospital networks and public health labs, addressing increased demand during the Canadian flu and respiratory virus season.
In February 2024, Roche Diagnostics signed a collaboration with Canada-based Medicago to co-develop a next-generation multiplex PCR panel targeting emerging and re-emerging pathogens, including avian influenza strains. The partnership aims to accelerate the launch of advanced diagnostic solutions that can mitigate future public health threats by expanding the scope of rapid molecular infectious disease testing across North America.
Press Releases